| Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B. 1.617. 2) and Omicron (B. 1.1. 529) variants—United States, June 2021–January 2022 AS Lambrou MMWR. Morbidity and mortality weekly report 71, 2022 | 149 | 2022 |
| Genomic surveillance for SARS-CoV-2 variants circulating in the United States, December 2020–May 2021 P Paul MMWR. Morbidity and mortality weekly report 70, 2021 | 86 | 2021 |
| Outbreak of SARS-CoV-2 B. 1.617. 2 (Delta) variant infections among incarcerated persons in a federal prison—Texas, July–August 2021 LM Hagan MMWR. Morbidity and Mortality Weekly Report 70, 2021 | 60 | 2021 |
| SARS-CoV-2 Delta–Omicron Recombinant Viruses, United States KA Lacek, BL Rambo-Martin, D Batra, X Zheng, N Hassell, H Sakaguchi, ... Emerging infectious diseases 28 (7), 1442, 2022 | 49 | 2022 |
| Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines L Wang, MH Kainulainen, N Jiang, H Di, G Bonenfant, L Mills, M Currier, ... Nature communications 13 (1), 4350, 2022 | 41 | 2022 |
| Genomic surveillance for SARS-CoV-2 variants: circulation of omicron lineages—United States, January 2022–May 2023 KC Ma MMWR. Morbidity and Mortality Weekly Report 72, 2023 | 38 | 2023 |
| Canalization and robustness in human genetics and disease G Gibson, KA Lacek Annual Review of Genetics 54, 189-211, 2020 | 23 | 2020 |
| Assessment of clinical and virological characteristics of SARS-CoV-2 infection among children aged 0 to 4 years and their household members RA Karron, MK Hetrich, YB Na, MD Knoll, E Schappell, J Meece, ... JAMA Network Open 5 (8), e2227348-e2227348, 2022 | 17 | 2022 |
| Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐and Delta‐related outpatient illness among adults, October 2021–February 2022 SS Kim, JR Chung, HK Talbot, CG Grijalva, KJ Wernli, E Kiniry, ET Martin, ... Influenza and Other Respiratory Viruses 16 (6), 975-985, 2022 | 12 | 2022 |
| Amplification artifact in SARS-CoV-2 Omicron sequences carrying P681R mutation, New York, USA A Heguy, D Dimartino, C Marier, P Zappile, E Guzman, R Duerr, G Wang, ... Emerging infectious diseases 28 (4), 881, 2022 | 9 | 2022 |
| Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants N Jiang, L Wang, M Hatta, C Feng, M Currier, X Lin, J Hossain, D Cui, ... bioRxiv, 2023.01. 08.523127, 2023 | 6 | 2023 |
| Identification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in the United States. bioRxiv 2022 KA Lacek, BL Rambo-Martin, D Batra, X Zheng, H Sakaguchi, T Peacock, ... Google Scholar, 0 | 6 | |
| Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the US throughout the Delta to Omicron Waves H Di, EA Pusch, J Jones, NA Kovacs, N Hassell, M Sheth, KS Lynn, ... Vaccines 12 (5), 505, 2024 | | 2024 |
| Targeted amplification and genetic sequencing of the severe acute respiratory syndrome coronavirus 2 surface glycoprotein MW Keller, LM Keong, BL Rambo-Martin, N Hassell, KA Lacek, ... Microbiology Spectrum 12 (1), e02982-23, 2024 | | 2024 |
| Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants (preprint) N Jiang, L Wang, M Hatta, C Feng, M Currier, X Lin, J Hossain, D Cui, ... | | 2023 |
| Identification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in the United States (preprint) KA Lacek, B Rambo-Martin, D Batra, X Zheng, MW Keller, M Wilson, ... | | 2022 |
| Identification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in the United States KA Lacek, B Rambo-Martin, D Batra, X Zheng, MW Keller, M Wilson, ... bioRxiv, 2022 | | 2022 |
| Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B. 1.617. 2) and Omicron (B. 1.1. 529) Variants-United States, June 2021-January 2022 (vol 71, 2022) AS Lambrou, P Shirk, MK Steele, P Paul, CR Paden, B Cadwell, ... Mmwr-Morbidity and Mortality Weekly Report, 528-528, 2022 | | 2022 |
| Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines (preprint) L Wang, MH Kainulainen, N Jiang, H Di, G Bonenfant, L Mills, M Currier, ... | | 2021 |
